Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Black Diamond Therapeutics, Inc. (BDTX : NSDQ)

• Company Description    Black Diamond Therapeutics Inc. is an oncology medicine company. It engages in discovery and development of small molecule, tumor-agnostic therapies. The company's lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor and tyrosine-protein kinase. Black Diamond Therapeutics Inc. is based in Cambridge, Massachusetts. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $2.87 Daily Weekly Monthly 20 Day Moving Average: 635,389 shares Shares Outstanding: 57.29 (millions) Market Capitalization: $164.42 (millions) Beta: 3.38 52 Week High: $4.94 52 Week Low: $1.31 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 32.26% 24.76% 12 Week 11.67% 9.33% Year To Date 18.11% 15.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE MAIN STREET 14TH FLOOR - CAMBRIDGE,MA 02142 USA ph: 617-252-0848 fax: - investors@bdtx.com None

• General Corporate Information    Officers Mark A. Velleca - Chief Executive Officer; Chairman; President and D Erika Jones - Senior Vice President Ali Behbahani - Director Samarth Kulkarni - Director Shannon Campbell - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09203E105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/11/26 Share - Related Items Shares Outstanding: 57.29 Most Recent Split Date: (:1) Beta: 3.38 Market Capitalization: $164.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.18 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.62 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 5.74 PEG Ratio: - Price Ratios Price/Book: 1.46 Price/Cash Flow: 5.44 Price / Sales: - EPS Growth vs. Year Ago Period: 50.00% vs. Previous Quarter: 6.67% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - - 12/31/25 - 23.19 09/30/25 - 17.78 ROA 03/31/26 - - 12/31/25 - 18.48 09/30/25 - 13.80 Current Ratio 03/31/26 - - 12/31/25 - 8.42 09/30/25 - 8.94 Quick Ratio 03/31/26 - - 12/31/25 - 8.42 09/30/25 - 8.94 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - 31.95 09/30/25 - 30.71 Book Value 03/31/26 - - 12/31/25 - 1.97 09/30/25 - 2.21 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - - 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©